

Marta Mosca

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/448622/publications.pdf>

Version: 2024-02-01

166
papers

10,338
citations

71061

41
h-index

37183

96
g-index

166
all docs

166
docs citations

166
times ranked

9183
citing authors

#	ARTICLE	IF	CITATIONS
1	2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 736-745.	0.5	1,265
2	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019, 71, 1400-1412.	2.9	1,098
3	An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. <i>European Respiratory Journal</i> , 2015, 46, 976-987.	3.1	803
4	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1151-1159.	0.5	759
5	EULAR recommendations for the management of antiphospholipid syndrome in adults. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1296-1304.	0.5	664
6	Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 958-967.	0.5	558
7	2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 713-723.	0.5	463
8	Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. <i>Lancet, The</i> , 2018, 392, 222-231.	6.3	396
9	Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005, 19, 685-708.	1.4	281
10	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 554-561.	0.5	268
11	Development and validation of a new algorithm for attribution of neuropsychiatric events in systemic lupus erythematosus. <i>Rheumatology</i> , 2015, 54, 891-898.	0.9	129
12	“To Be or Not To Be,” Ten Years After: Evidence for Mixed Connective Tissue Disease as a Distinct Entity. <i>Seminars in Arthritis and Rheumatism</i> , 2012, 41, 589-598.	1.6	126
13	The diagnosis and classification of undifferentiated connective tissue diseases. <i>Journal of Autoimmunity</i> , 2014, 48-49, 50-52.	3.0	119
14	The diagnosis and classification of mixed connective tissue disease. <i>Journal of Autoimmunity</i> , 2014, 48-49, 46-49.	3.0	101
15	Low FODMAP Diet: Evidence, Doubts, and Hopes. <i>Nutrients</i> , 2020, 12, 148.	1.7	99
16	Salivary gland ultrasonography: a highly specific tool for the early diagnosis of primary Sjögren’s syndrome. <i>Arthritis Research and Therapy</i> , 2015, 17, 146.	1.6	94
17	How Do Patients With Newly Diagnosed Systemic Lupus Erythematosus Present? A Multicenter Cohort of Early Systemic Lupus Erythematosus to Inform the Development of New Classification Criteria. <i>Arthritis and Rheumatology</i> , 2019, 71, 91-98.	2.9	93
18	Systemic sclerosis: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2019, 4, e000782.	1.8	91

#	ARTICLE	IF	CITATIONS
19	Fetal outcome and recommendations of pregnancies in lupus nephritis in the 21st century. A prospective multicenter study. <i>Journal of Autoimmunity</i> , 2016, 74, 6-12.	3.0	89
20	Leukopenia, lymphopenia, and neutropenia in systemic lupus erythematosus: Prevalence and clinical impact—A systematic literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 45, 190-194.	1.6	88
21	Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study. <i>Journal of Autoimmunity</i> , 2018, 86, 1-8.	3.0	86
22	Maternal outcome in pregnant women with lupus nephritis. A prospective multicenter study. <i>Journal of Autoimmunity</i> , 2016, 74, 194-200.	3.0	80
23	Renal flares in 91 SLE patients with diffuse proliferative glomerulonephritis. <i>Kidney International</i> , 2002, 61, 1502-1509.	2.6	73
24	A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study. <i>Frontiers in Pharmacology</i> , 2016, 7, 380.	1.6	72
25	COVID-19: the new challenge for rheumatologists. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 175-180.	0.4	69
26	Defining unclassifiable connective tissue diseases: incomplete, undifferentiated, or both?. <i>Journal of Rheumatology</i> , 2005, 32, 213-5.	1.0	67
27	Systemic lupus erythematosus: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2019, 4, e000793.	1.8	66
28	Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study. <i>Clinical Rheumatology</i> , 2018, 37, 2233-2240.	1.0	64
29	Undifferentiated CTD: A wide spectrum of autoimmune diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2012, 26, 73-77.	1.4	60
30	Remission and low disease activity in systemic lupus erythematosus: an achievable goal even with fewer steroids? Real-life data from a monocentric cohort. <i>Lupus Science and Medicine</i> , 2018, 5, e000234.	1.1	59
31	Undifferentiated connective tissue diseases (UCTD): a new frontier for rheumatology. <i>Best Practice and Research in Clinical Rheumatology</i> , 2007, 21, 1011-1023.	1.4	57
32	Undifferentiated connective tissue disease: analysis of 83 patients with a minimum followup of 5 years. <i>Journal of Rheumatology</i> , 2002, 29, 2345-9.	1.0	57
33	Undifferentiated connective tissue diseases (UCTD): Simplified systemic autoimmune diseases. <i>Autoimmunity Reviews</i> , 2011, 10, 256-258.	2.5	56
34	Early treatment with hydroxychloroquine prevents the development of endothelial dysfunction in a murine model of systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2015, 17, 277.	1.6	55
35	Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 449-56.	0.4	55
36	Prevalence and clinico-serological correlations of anti-alpha-enolase, anti-C1q, and anti-dsDNA antibodies in patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2006, 33, 695-7.	1.0	53

#	ARTICLE	IF	CITATIONS
37	Glucocorticoid withdrawal in systemic lupus erythematosus: are remission and low disease activity reliable starting points for stopping treatment? A real-life experience. <i>RMD Open</i> , 2019, 5, e000916.	1.8	51
38	Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 634-640.	0.5	51
39	Prognostic Value of Lung Ultrasound B-Lines in Systemic Sclerosis. <i>Chest</i> , 2020, 158, 1515-1525.	0.4	50
40	The role of imaging in the evaluation of joint involvement in 102 consecutive patients with systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2015, 14, 10-15.	2.5	48
41	Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria. <i>Journal of Rheumatology</i> , 2019, 46, 721-726.	1.0	45
42	Disease activity assessment of rheumatic diseases during pregnancy: a comprehensive review of indices used in clinical studies. <i>Autoimmunity Reviews</i> , 2019, 18, 164-176.	2.5	44
43	First Report of the Italian Registry on Immune-Mediated Congenital Heart Block (Lu.Ne Registry). <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 11.	1.1	39
44	Thigh magnetic resonance imaging for the evaluation of disease activity in patients with idiopathic inflammatory myopathies followed in a single center. <i>Muscle and Nerve</i> , 2016, 54, 666-672.	1.0	38
45	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 775-781.	0.5	37
46	Long-Term Retention Rate of Anakinra in Adult Onset Still's Disease and Predictive Factors for Treatment Response. <i>Frontiers in Pharmacology</i> , 2019, 10, 296.	1.6	35
47	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1333-1339.	0.5	35
48	A Low-FODMAP Diet for Irritable Bowel Syndrome: Some Answers to the Doubts from a Long-Term Follow-Up. <i>Nutrients</i> , 2020, 12, 2360.	1.7	34
49	Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies. <i>Lupus Science and Medicine</i> , 2021, 8, e000590.	1.1	31
50	Remission in systemic lupus erythematosus: testing different definitions in a large multicentre cohort. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 943-950.	0.5	30
51	Undifferentiated connective tissue disease: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2019, 4, e000786.	1.8	28
52	Associations Between Classification Criteria Items in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2020, 72, 1820-1826.	1.5	28
53	Cell-free DNA in the plasma of patients with systemic sclerosis. <i>Clinical Rheumatology</i> , 2009, 28, 1437-1440.	1.0	27
54	Vitamin D in early primary Sjögren's syndrome: does it play a role in influencing disease phenotypes?. <i>Rheumatology International</i> , 2014, 34, 1159-1164.	1.5	27

#	ARTICLE	IF	CITATIONS
55	The Association of Sjögren Syndrome and Autoimmune Thyroid Disorders. <i>Frontiers in Endocrinology</i> , 2018, 9, 121.	1.5	26
56	Cystatin C a candidate biomarker for severity of submandibular gland involvement in Sjögren's syndrome. <i>Rheumatology</i> , 2017, 56, 1031-1038.	0.9	25
57	Anakinra Drug Retention Rate and Predictive Factors of Long-Term Response in Systemic Juvenile Idiopathic Arthritis and Adult Onset Still Disease. <i>Frontiers in Pharmacology</i> , 2019, 10, 918.	1.6	25
58	Disease knowledge index and perspectives on reproductive issues: A nationwide study on 398 women with autoimmune rheumatic diseases. <i>Joint Bone Spine</i> , 2019, 86, 475-481.	0.8	25
59	Risk factors of damage in early diagnosed systemic lupus erythematosus: results of the Italian multicentre Early Lupus Project inception cohort. <i>Rheumatology</i> , 2020, 59, 2272-2281.	0.9	25
60	The patient's perspective: are quality of life and disease burden a possible treatment target in systemic lupus erythematosus?. <i>Rheumatology</i> , 2020, 59, v63-v68.	0.9	25
61	Neutrophil Extracellular Traps in the Autoimmunity Context. <i>Frontiers in Medicine</i> , 2021, 8, 614829.	1.2	25
62	Saliva as an ideal milieu for emerging diagnostic approaches in primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, 785-90.	0.4	25
63	Treat to target, remission and low disease activity in SLE. <i>Best Practice and Research in Clinical Rheumatology</i> , 2017, 31, 342-350.	1.4	24
64	Ehlers-Danlos syndromes: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2018, 4, e000790.	1.8	23
65	Impact of fatigue on health-related quality of life and illness perception in a monocentric cohort of patients with systemic lupus erythematosus. <i>RMD Open</i> , 2020, 6, e001133.	1.8	23
66	Phenotyping multiple subsets in Sjögren's syndrome: a salivary proteomic SWATH-MS approach towards precision medicine. <i>Clinical Proteomics</i> , 2019, 16, 26.	1.1	22
67	MRI pattern of arthritis in systemic lupus erythematosus: a comparative study with rheumatoid arthritis and healthy subjects. <i>Skeletal Radiology</i> , 2015, 44, 261-266.	1.2	21
68	Pregnancy and undifferentiated connective tissue disease: outcome and risk of flare in 100 pregnancies. <i>Rheumatology</i> , 2020, 59, 1335-1339.	0.9	21
69	Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes. <i>Frontiers in Medicine</i> , 2020, 7, 42.	1.2	21
70	Are remission and low disease activity state ideal targets for pregnancy planning in systemic lupus erythematosus? A multicentre study. <i>Rheumatology</i> , 2021, 60, 5610-5619.	0.9	21
71	Differentiating between UCTD and early-stage SLE: from definitions to clinical approach. <i>Nature Reviews Rheumatology</i> , 2022, 18, 9-21.	3.5	21
72	Treat-to-target in systemic lupus erythematosus: where are we today?. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, S112-5.	0.4	21

#	ARTICLE	IF	CITATIONS
73	Illness perception in systemic lupus erythematosus patients: The roles of alexithymia and depression. <i>Comprehensive Psychiatry</i> , 2015, 63, 88-95.	1.5	20
74	Celiac Disease Prevalence Is Increased in Primary Sjögren's Syndrome and Diffuse Systemic Sclerosis: Lessons from a Large Multi-Center Study. <i>Journal of Clinical Medicine</i> , 2019, 8, 540.	1.0	20
75	A case of undifferentiated connective tissue disease: is it a distinct clinical entity?. <i>Nature Clinical Practice Rheumatology</i> , 2008, 4, 328-332.	3.2	18
76	Impact of first wave of SARS-CoV-2 infection in patients with Systemic Lupus Erythematosus: Weighting the risk of infection and flare. <i>PLoS ONE</i> , 2021, 16, e0245274.	1.1	18
77	Systemic lupus erythematosus and the economic perspective: a systematic literature review and points to consider. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, S116-22.	0.4	18
78	Cross-cultural validation of Lupus Impact Tracker in five European clinical practice settings. <i>Rheumatology</i> , 2017, 56, 818-828.	0.9	17
79	Articular involvement, steroid treatment and fibromyalgia are the main determinants of patient-physician discordance in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2020, 22, 241.	1.6	17
80	Low Preconception Complement Levels Are Associated with Adverse Pregnancy Outcomes in a Multicenter Study of 260 Pregnancies in 197 Women with Antiphospholipid Syndrome or Carriers of Antiphospholipid Antibodies. <i>Biomedicines</i> , 2021, 9, 671.	1.4	17
81	The interaction between anti-Ro/SSA and anti-La/SSB autoantibodies and anti-infectious antibodies in a wide spectrum of auto-immune diseases: another angle of the autoimmune mosaic. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 929-935.	0.4	17
82	Minor salivary gland biopsy and Sjögren's syndrome: comparative analysis of biopsies among different Italian rheumatologic centers. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, 929-33.	0.4	16
83	COVID-19: the new challenge for rheumatologists. First update. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 373-382.	0.4	15
84	LJP-394 (abetimus sodium) in the treatment of systemic lupus erythematosus. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 873-879.	0.9	14
85	TNF-alpha inhibitors in Systemic Lupus Erythematosus. A case report and a systematic literature review. <i>Modern Rheumatology</i> , 2015, 25, 642-645.	0.9	14
86	Is there a role for laser speckle contrast analysis (LASCA) in predicting the outcome of digital ulcers in patients with systemic sclerosis?. <i>Clinical Rheumatology</i> , 2020, 39, 69-75.	1.0	14
87	Muscular vasculitis confined to lower limbs: description of two case reports and a review of the literature. <i>Rheumatology International</i> , 2017, 37, 2115-2121.	1.5	13
88	Emerging trends in Sjögren's syndrome: basic and translational research. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, 779-84.	0.4	13
89	Analysis of the evolution of UCTD to defined CTD after a long term follow-up. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 471.	0.4	13
90	Vascular reactivity in patients with undifferentiated connective tissue diseases. <i>Atherosclerosis</i> , 2009, 203, 185-191.	0.4	12

#	ARTICLE	IF	CITATIONS
91	High sensitivity troponin might be a marker of subclinical scleroderma heart involvement: a preliminary study. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 183-187.	1.0	12
92	Tacrolimus in non-Asian patients with SLE: a real-life experience from three European centres. <i>Lupus Science and Medicine</i> , 2018, 5, e000274.	1.1	12
93	The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases: insights after the first 5 years of the ERN ReCONNET. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 3-11.	0.4	12
94	Occurrence of organ-specific and systemic autoimmune diseases among the first- and second-degree relatives of Caucasian patients with connective tissue diseases: report of data obtained through direct patient interviews. <i>Clinical Rheumatology</i> , 2008, 27, 1045-1048.	1.0	11
95	Treatment for refractory lupus nephritis: Rituximab vs triple target therapy. <i>Autoimmunity Reviews</i> , 2019, 18, 102406.	2.5	11
96	Withdrawal of therapy in non-renal systemic lupus erythematosus: is this an achievable goal?. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, S71-4.	0.4	11
97	Prognostic value of flow mediated dilation in patients with systemic lupus erythematosus: A pilot prospective cohort study. <i>Atherosclerosis</i> , 2014, 236, 381-384.	0.4	10
98	Treatment with Allogenic Mesenchymal Stromal Cells in a Murine Model of Systemic Lupus Erythematosus. <i>International Journal of Stem Cells</i> , 2017, 10, 160-168.	0.8	10
99	Sexual dysfunction in Behçet's syndrome. <i>Rheumatology International</i> , 2020, 40, 9-15.	1.5	10
100	New drugs in systemic lupus erythematosus: when to start and when to stop. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, S82-5.	0.4	10
101	Health information technologies in systemic lupus erythematosus: focus on patient assessment. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S54-S56.	0.4	10
102	Development of de novo major involvement during follow-up in Behçet's syndrome. <i>Clinical Rheumatology</i> , 2016, 35, 247-250.	1.0	9
103	Shaping the Future of Rare Diseases after a Global Health Emergency: Organisational Points to Consider. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 8694.	1.2	9
104	Multicentric study comparing cyclosporine, mycophenolate mofetil and azathioprine in the maintenance therapy of lupus nephritis: 8 years follow up. <i>Journal of Nephrology</i> , 2021, 34, 389-398.	0.9	9
105	Epidemiology of systemic sclerosis: a multi-database population-based study in Tuscany (Italy). <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 90.	1.2	9
106	Quality indicators for systemic lupus erythematosus based on the 2019 EULAR recommendations: development and initial validation in a cohort of 220 patients. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1175-1182.	0.5	9
107	Serum IgG2 antibody multicomposition in systemic lupus erythematosus and lupus nephritis (Part 1): cross-sectional analysis. <i>Rheumatology</i> , 2021, 60, 3176-3188.	0.9	9
108	Outcomes, rates and predictors of transition of isolated Raynaud's phenomenon: a systematic review and meta-analysis. <i>Swiss Medical Weekly</i> , 2017, 147, w14506.	0.8	9

#	ARTICLE	IF	CITATIONS
109	MicroRNA-mediated Regulation of Mucin-type O-glycosylation Pathway: A Putative Mechanism of Salivary Gland Dysfunction in Sjögren Syndrome. <i>Journal of Rheumatology</i> , 2019, 46, 1485-1494.	1.0	8
110	Topic Modeling and User Network Analysis on Twitter during World Lupus Awareness Day. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 5440.	1.2	8
111	Serum IgG2 antibody multi-composition in systemic lupus erythematosus and in lupus nephritis (Part) <i>Tj ETQq1 1 0,784314 rgBT /Over</i>	0.9	8
112	Pediatric Systemic Lupus Erythematosus: Learning From Longer Follow Up to Adulthood. <i>Frontiers in Pediatrics</i> , 2018, 6, 144.	0.9	7
113	Hydroxychloroquine availability during COVID-19 crisis and its effect on patient anxiety. <i>Lupus Science and Medicine</i> , 2021, 8, e000496.	1.1	7
114	Evaluating the Construct of Damage in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2023, 75, 998-1006.	1.5	7
115	Clinical practice guidelines: the first year of activity of the European Reference Network on Rare and Complex Connective Tissue and Musculoskeletal Diseases (ERN ReCONNET). <i>RMD Open</i> , 2019, 4, e000791.	1.8	6
116	Real life picture of the use of intravenous immunoglobulins in idiopathic inflammatory myopathies: Results of a multicentric study. <i>Autoimmunity Reviews</i> , 2021, 20, 102757.	2.5	6
117	Second Wave Antibodies in Autoimmune Renal Diseases: The Case of Lupus Nephritis. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 3020-3023.	3.0	6
118	Behçet's syndrome and psychiatric involvement: is it a primary or secondary feature of the disease?. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 125-128.	0.4	6
119	Empowering Patients in the Therapeutic Decision-Making Process: A Glance Into Behçet's Syndrome. <i>Frontiers in Medicine</i> , 2021, 8, 769870.	1.2	6
120	Bioelectrical Impedance Vector Analysis for Nutritional Status Assessment in Systemic Sclerosis and Association With Disease Characteristics. <i>Journal of Rheumatology</i> , 2021, 48, 728-734.	1.0	5
121	Definition and application of proximal-distal gradient finger perfusion in systemic sclerosis by laser speckle contrast analysis. <i>Microvascular Research</i> , 2022, 140, 104307.	1.1	5
122	Framingham, ACC/AHA or QRISK3: which is the best in systemic lupus erythematosus cardiovascular risk estimation?. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 602-608.	0.4	5
123	Self-Reported Anxiety and Depression in a Monocentric Cohort of Patients With Systemic Lupus Erythematosus: Analysis of Prevalence, Main Determinants, and Impact on Quality of Life. <i>Frontiers in Medicine</i> , 2022, 9, 859840.	1.2	5
124	COVID-19: the new challenge for rheumatologists. One year later. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 203-213.	0.4	5
125	Rare clinical manifestations in systemic lupus erythematosus: a review on frequency and clinical presentation. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 93-102.	0.4	5
126	Systemic sclerosis chronic ulcers: preliminary results of treatment with allogenic skin grafting in a cohort of Italian patients. <i>International Wound Journal</i> , 2016, 13, 1050-1051.	1.3	4

#	ARTICLE	IF	CITATIONS
127	Personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variables. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 2097-2111.	0.9	4
128	Assessment of swallowing function with oroâ€pharyngealâ€esophageal scintigraphy in patients with idiopathic inflammatory myopathies. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13599.	1.6	4
129	The impact of skin calcinosis on digital ulcers in patients with SSc : clinical and prognostic stratification using the â€wound bed scoreâ€. <i>International Wound Journal</i> , 2020, 17, 1783-1790.	1.3	4
130	Imaging of joints in systemic lupus erythematosus. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 114, 68-73.	0.4	4
131	Are patients with systemic lupus erythematosus more prone to result false-positive for SARS-CoV2 serology?. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 577.	0.4	4
132	Impact of low-dose acetylsalicylic acid on pregnancy outcome in systemic lupus erythematosus: results from a multicentre study. <i>Lupus Science and Medicine</i> , 2022, 9, e000714.	1.1	4
133	Hydroxychloroquine in patients with rheumatic diseases during the COVID-19 pandemic: a letter to clinicians. <i>Lancet Rheumatology, The</i> , 2020, 2, e735-e736.	2.2	3
134	SjÃgren's syndrome and other rare and complex connective tissue diseases: an intriguing liaison. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 103-112.	0.4	3
135	Coping with systemic lupus erythematosus in patientsâ€™ words. <i>Lupus Science and Medicine</i> , 2022, 9, e000656.	1.1	3
136	Long-term Outcome of Children Born to Women with Autoimmune Rheumatic Diseases: A Multicentre, Nationwide Study on 299 Randomly Selected Individuals. <i>Clinical Reviews in Allergy and Immunology</i> , 2022, 62, 346-353.	2.9	2
137	UCTD and SLE patients show increased levels of oxidative and DNA damage together with an altered kinetics of DSB repair. <i>Mutagenesis</i> , 2021, 36, 429-436.	1.0	2
138	Cardiovascular burden in systemic sclerosis: QRISK3 versus Framingham for risk estimation. <i>Modern Rheumatology</i> , 2022, 32, 584-588.	0.9	2
139	Future prospects for salivary proteomics in rheumatology: the example of eosinophil granulomatosis with polyangiitis. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, 810-1.	0.4	2
140	Adherence to treatment in BehÃset's syndrome: a multi-faceted issue. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 88-93.	0.4	2
141	COVID-19 mRNA vaccine booster in patients with autoimmune rheumatic diseases. <i>Rheumatology</i> , 2022, 61, e328-e330.	0.9	2
142	What are the topics you care about making trials in lupus more effective? Results of an Open Space meeting of international lupus experts. <i>Lupus Science and Medicine</i> , 2021, 8, e000506.	1.1	1
143	How do systemic lupus erythematosus patients with very-long disease duration present? Analysis of a monocentric cohort. <i>Lupus</i> , 2021, 30, 439-447.	0.8	1
144	COVID-19: the new challenge for rheumatologists. One year later. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 203-213.	0.4	1

#	ARTICLE	IF	CITATIONS
145	Evaluation of Interstitial Lung Disease in Idiopathic Inflammatory Myopathies Through Semiquantitative and Quantitative Analysis of Lung Computed Tomography. <i>Journal of Thoracic Imaging</i> , 2022, 37, 344-351.	0.8	1
146	Use of Biological Drugs for Psoriasis: A Drug-Utilization Study Using Tuscan Administrative Databanks. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 6799.	1.2	1
147	Unveiling Deficiency of Adenosine Deaminase 2: An Adult Patient With Recurrent Strokes, Vasculitic Ulcers, and Bowel Perforation. <i>Journal of Rheumatology</i> , 0, , jrheum.220218.	1.0	1
148	Morphologic ultrasonography of the temporal artery for diagnosis of giant cell arteritis: Brief report. <i>Modern Rheumatology</i> , 2019, 29, 717-719.	0.9	0
149	FP141 MULTICENTRIC STUDY COMPARING CYCLOSPORINE, MYCOPHENOLATE MOFETIL AND AZATHIOPRINE IN THE MAINTENANCE THERAPY OF LUPUS NEPHRITIS: 10 YEARS FOLLOW UP. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.4	0
150	Do systemic steroids increase the risk of ocular complication in uveitis patients? Focus on a Italian referral center. <i>Clinical Rheumatology</i> , 2019, 38, 2917-2923.	1.0	0
151	OP0046â€¦MULTICENTRIC STUDY COMPARING CYCLOSPORINE, MYCOPHENOLATE MOFETIL AND AZATHIOPRINE IN THE MAINTENANCE THERAPY OF LUPUS NEPHRITIS: 10 YEARS FOLLOW UP. , 2019, , .		0
152	SAT0175â€¦ULTRA-HIGH-FREQUENCY ULTRASOUND OF LABIAL SALIVARY GLANDS HIGHLY CORRELATES WITH HISTOPATHOLOGY IN PRIMARY SJÄ–GRENâ€™S SYNDROME. , 2019, , .		0
153	FRI0223â€¦EXTRACELLULAR VESICLES AS A SOURCE OF BIOMARKERS IN SJÄ–GREN SYNDROME: A SWATH-MS PROTEOMIC APPROACH. , 2019, , .		0
154	THU0284â€¦WHAT DO HEMATOLOGICAL ABNORMALITIES TELL US IN SLE? RESULTS FROM TWO INDEPENDENT MULTICENTER EUROPEAN SLE COHORTS. , 2019, , .		0
155	AB1289â€¦TESTING DIFFERENT ITEMS INCLUDED IN THE DEFINITION OF REMISSION IN A MULTICENTRE SLE COHORT. , 2019, , .		0
156	THU0259â€¦ULTRASOUND OF MAJOR SALIVARY GLANDS IDENTIFIES PATIENTS WITH MORE COMPLEX SALIVARY GLAND HISTOPATHOLOGY BUT NOT MILD LESIONS. , 2019, , .		0
157	SAT0260â€¦MUSCULAR INVOLVEMENT OF THE LOWER LIMBS IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES: A MRI EVALUATION. , 2019, , .		0
158	AB0510â€¦LUNG ULTRASOUND OF PLEURAL IRREGULARITIES IN SUB-CLINICAL PRIMARY SJÄ–GRENâ€™S SYNDROME-LUNG INVOLVEMENT: A SINGLE CENTRE EXPERIENCE. , 2019, , .		0
159	Translation, cultural adaptation and validation of the Italian version of the Brief Index of Lupus Damage: the BILDit. <i>Lupus</i> , 2020, 29, 1198-1205.	0.8	0
160	P175â€¦Despite the high rate of response to treatment, lupus nephritis standard of care is still associated with high incidence of chronic kidney disease: a retrospective longitudinal study, from three south-European cohorts of patients in follow-up since 2000. , 2020, , .		0
161	O8â€¦Performance of the EULAR/ACR 2019 classification criteria for systemic lupus erythematosus in men, ethnicities, and early disease. , 2020, , .		0
162	Cardiometabolic risk and subclinical vascular damage assessment in idiopathic inflammatory myopathies: a challenge for the clinician. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 1036-1043.	0.4	0

#	ARTICLE	IF	CITATIONS
163	Adherence to treatment in Behçet's syndrome: a multi-faceted issue. Clinical and Experimental Rheumatology, 2021, 39 Suppl 132, 88-93.	0.4	0
164	The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases: insights after the first 5 years of the ERN ReCONNECT.. Clinical and Experimental Rheumatology, 2022, , .	0.4	0
165	Sjögren's syndrome and other rare and complex connective tissue diseases: an intriguing liaison.. Clinical and Experimental Rheumatology, 2022, , .	0.4	0
166	OA01 Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. Rheumatology, 2022, 61, .	0.9	0